Arrowstreet Capital
TVTX icon

Arrowstreet Capital’s Travere Therapeutics TVTX Stock Holding History

Arrowstreet Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-268,045
Closed -$10.2M – 2099
2025
Q4 		$10.2M Sell
268,045
-60,609
-18% -$1.97M 0.01% 920
2025
Q3 		$7.85M Buy
+328,654
New +$6.18M 0.01% 1029
2020
Q3 		– Sell
-197,552
Closed -$4.03M – 2525
2020
Q2 		$4.03M Buy
+197,552
New +$3.15M 0.01% 1145
2018
Q2 		– Sell
-110,714
Closed -$2.48M – 1306
2018
Q1 		$2.48M Buy
110,714
+76,700
+225% +$1.83M 0.01% 712
2017
Q4 		$717K Buy
34,014
+22,114
+186% +$505K ﹤0.01% 1015
2017
Q3 		$296K Buy
+11,900
New +$262K ﹤0.01% 1006

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital's TVTX Position: Q1 2026 in Review

Arrowstreet Capital sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 268,045 shares — an estimated $10.2M sold.

Arrowstreet Capital first reported a position in TVTX in Q3 2017 and held it in 6 quarters. The position peaked at $10.2M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Arrowstreet Capital reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 268,045 Travere Therapeutics shares in Q1 2026, an estimated $10.2M.
  • Arrowstreet Capital first reported a position in Travere Therapeutics in Q3 2017 and held it in 6 quarters.
  • Arrowstreet Capital's Travere Therapeutics position peaked at $10.2M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.